Underwriters were given a 30-day option to purchase up to 1.74 million additional shares. ・Trevi is currently developing Haduvio, its treatment for chronic cough in patients with idiopathic pulmonary ...

Trevi Therapeutics shifts to late-stage biotech with Haduvio for IPF chronic cough. Click here to read my latest analysis of ...

VO2 max is a measure of the maximum amount of oxygen the body can handle during intense exercise. A doctor explains how it's ...

Trevi Therapeutics, Inc. TRVI shares are trading higher after the company announced the pricing of its $150 million offering ...

This Perspective reviews how AI is moving drug discovery from long, costly experimental pipelines toward earlier clinical ...

Background Sex-based differences in immune response are well established, but whether men and women derive comparable benefit ...

The case, detected in San Francisco, is the 16th in the U.S. so far of the newer, potentially more severe strain.

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients ...

The acquisition brings together the gold standard for continuous ambulatory cough monitoring and lung sound analysis ...

There seems to be a strong exposure-response relationship between nerandomilast and the preservation of FVC in patients with PPF and IPF.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...

In what shakes out to be the largest follow-on stock offering in biopharma history, Revolution Medicines Inc., an oncology company that was the subject of buyout rumors earlier this year, priced 10.56 ...